1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Telesis Bio, Inc.

Telesis Bio, Inc.

TBIO
Telesis Bio, Inc.US flagOther OTC
0.05
USD
+0.00
- -
4.15MMarket Cap

Total Valuation

Telesis Bio, Inc. carries a market capitalization of 4.15M, placing it among publicly traded companies globally. Its enterprise value stands at 62.13M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.15M
Enterprise Value62.13M

Share Statistics

Telesis Bio, Inc. currently has 1.77M shares outstanding.

Shares Outstanding1.77M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 0.36, and the price-to-book ratio stands at -0.03.

PE RatioN/A
PS Ratio0.36
PB Ratio-0.03
P/TBV Ratio-0.25
P/FCF Ratio-0.30
P/OCF Ratio-0.29

Enterprise Valuation

EV / Sales3.54
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Telesis Bio, Inc. maintains a current ratio of 1.89, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 357.46, indicating elevated leverage, while an interest coverage ratio of -10.39 demonstrates limited ability to service its debt obligations.

Current Ratio1.89
Quick Ratio1.44
Debt / Equity357.46
Debt / EBITDA-1.16
Interest Coverage-10.39

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-59.24
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.50

Taxes

Income Tax20,000.00
Effective Tax RateN/A

Stock Price Statistics

Telesis Bio, Inc.'s stock has gained approximately 6% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.07.

Beta (5Y)N/A
52-Week Price Change6%
50-Day Moving Average0.04
200-Day Moving Average0.07
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Telesis Bio, Inc. generated 17.53M in revenue and converted that into -49.54M in net income, yielding earnings per share of -28.05. EBITDA reached -30.69M, while operating income came in at -35.21M.

Revenue17.53M
Gross Profit8.39M
Operating Income-35.21M
Pretax Income-48.50M
Net Income-49.54M
EBITDA-30.69M
EBIT-35.21M
Earnings Per Share (EPS)-28.05

Balance Sheet

Telesis Bio, Inc. holds 10.21M in cash and equivalents against 35.55M in total debt, resulting in a net debt position of -1.12M. Total book value stands at -182.69M, with working capital of 7.14M providing operational flexibility.

Cash & Cash Equivalents10.21M
Total Debt35.55M
Net Debt-1.12M
Equity (Book Value)-182.69M
Book Value Per Share-105.63
Working Capital7.14M

Cash Flow

Telesis Bio, Inc. produced -21.78M in operating cash flow over the past twelve months. After subtracting -1.01M in capital expenditures, free cash flow totaled -22.79M - equivalent to -13.18 per share.

Operating Cash Flow-21.78M
Capital Expenditures-1.01M
Free Cash Flow-22.79M
FCF Per Share-13.18

Margins

Telesis Bio, Inc. operates with a gross margin of 47.88, reflecting its pricing power and cost economics. The operating margin of -200.83 and net profit margin of -282.59 provide insight into operational efficiency.

Gross Margin47.88
Operating Margin-200.83
Pretax Margin-276.63
Profit Margin-282.59
EBITDA Margin-175.06

Dividends & Yields

The company's payout ratio of 4.58 indicates the proportion of earnings distributed to shareholders.

Dividend Per ShareN/A
Dividend YieldN/A
Payout Ratio4.58
Shareholder Yield240.10
FCF Yield-329.06

Stock Splits

Telesis Bio, Inc.'s most recent stock split took place on May 9, 2024 with a 18:1 split ratio.

Last Split Date5/9/2024
Split Ratio18:1

Scores

Telesis Bio, Inc. posts an Altman Z-Score of -7.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-7.05